Site & patient solutions case studies
See how we are supporting patients and sites for efficient clinical trial operations
Explore our library of case studies for patient centric clinical trial services.
An end-to-end solution providing the support and structure to efficiently operationalise clinical trials. Site & Patient Solutions offers faster study start-up, increased patient enrolment and retention, and site training and support to ensure compliance, quality data and inspection readiness.
Increased compliance for complex Alzheimer’s disease study
The sponsor in this case was a large pharmaceutical company that contracted ICON to manage and streamline the training and compliance workload for their phase 2 Alzheimer’s study.
In-Home Services: Trial continuity during COVID-19
A biopharmaceutical company was running a global 4-study program evaluating the long-term safety and effectiveness of a study drug in adult patients with a rare, inherited disease impacting the kidneys and other vital organs.
Flexible and meticulous management
A large pharma sponsor was conducting a Phase 2/3 randomised, placebo-controlled COVID-19 vaccine study. Facing labour and supply shortages, as well as unprecedented safety challenges due to the ongoing pandemic, the sponsor contracted Accellacare to support their staffing, enrollment, and logistics across seven US sites.
.jpg?crop=yes&w=1920&h=1010&a=0,135&itok=-xofypDS "Nurse-in-scrubs-child-engagement-(2)"){kind=icon}
In-Home Services: Rescue: accelerated patient recruitment
A biotechnology company was attempting to recruit 40 paediatric patients in a US phase II oncology study.
In-Home Services: Patient satisfaction levels in rare disease
Large pharmaceutical company was running a phase II study to assess the efficacy of a study drug in paediatric patients with a rare degenerative genetic disorder. The study required weekly infusions for more than 50 patients in the UK.
Overcoming challenges in non small cell lung carcinoma rescue study
A mid sized Pharma organisation was conducting a Phase Ib trial with plans to enroll 188 Non Small Cell Lung Carcinoma patients in Cohort B.
Patient insights & strategy
We developed and facilitated a series of Patient Partner Workshops™. Patients engaged in a variety of unique activities designed to stimulate open, honest dialogue among the group.
Agile operations drive enrollment in COVID-19 treatment studies
A mid-sized biopharmaceutical sponsor was conducting a phase 3 study on CDKL5 deficiency disorder, a rare
genetic seizure disorder in children.
genetic seizure disorder in children.
In-Home Services: Special populations and procedures
A global biopharmaceutical company was conducting a set of post-marketing studies to determine the safety and transference of a drug taken for autoimmune disorders during pregnancy and breastfeeding.
In-Home Services: Improved site productivity
A mid-size pharmaceutical company conducted a phase II study to compare treatments in 52 adult patients with plaque psoriasis. The treatment was to be applied twice daily for 3 weeks in 10 US sites.
In-Home Services: Expanding geographic reach
A small pharmaceutical company was conducting a Phase II study to evaluate the safety, efficacy and tolerability of an oral study drug to be taken twice daily. The study was targeting 32 adult patients (16-60 years old) with an inherited rare neurodegenerative movement disorder.
In-Home Services: Enhanced patient retention
A biopharmaceutical company ran multiple Phase II/III orphan drug studies evaluating a drug for a rare pulmonary disorder. The treatment regimen required daily oral dosing and safety blood draws every 2 weeks with a treatment duration of up to 2 years.